Michelle Carr, Author at BioTuesdays

Developments

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Inogen (NASDAQ:INGN) reported that the peer-reviewed journal, Pulmonary Therapy, has published a study demonstrating the association of portable oxygen concentrators with decreased mortality and increased cost...

June 5, 2024

Developments

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that a total of 25 clinical presentations highlighting TULSA procedure’s ability to effectively, safely and efficiently treat an unrivaled variety of prostate cancer...

May 6, 2024

Developments

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

BioRestorative Therapies (NASDAQ:BRTX) announced that it has entered into a five-year exclusive supply agreement with Cartessa Aesthetics. The goal of this transformative agreement is to combine BioRestorative’s deep...

April 30, 2024

Developments

PharmaJet creates two SABs

Closely-held PharmaJet created two scientific advisory boards (SABs) – infectious diseases and oncology – comprised of leading pharmaceutical industry experts in immunology, cancer, research, and policy shaping...

April 1, 2024

Markets

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

March 28, 2024

Developments

LENZ Therapeutics completes merger with Graphite Bio

LENZ Therapeutics (NASDAQ:LENZ) has completed its merger with Graphite Bio in an all-stock transaction. LENZ is advancing its lead assets, LNZ100 and LNZ101, which are both preservative-free, single-use, once-daily eye...

March 22, 2024

Developments

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Profound Medical (NASDAQ:PROF; TSX:PRN) announced a non-exclusive collaboration with Siemens Healthineers (XETRA:SHL) aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution...

February 28, 2024

Developments

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

IntelGenx (TSX:IGX; OTCQB:IGXT) announced positive results from a proof-of-concept study, conducted through a research collaboration with the University Prince Edward Island (UPEI), to assess the palatability, owner...

February 5, 2024

Developments

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

BioRestorative Therapies (NASDAQ:BRTX) announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society’s 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded...

February 5, 2024

Markets

Sigyn announces reverse split to support uplist to Nasdaq

Sigyn Therapeutics (OTCQB:SIGY) announced a 1-for-40 reverse split. Sigyn’s common stock is expected to begin trading on a split-adjusted basis on OTCQB when the market opens on Jan. 31. As a result of the split...

January 30, 2024

Author - Michelle Carr

Inogen shares published study results demonstrating association of portable oxygen therapy with increased survival and cost-effectiveness

Profound Medical highlights TULSA’s potential to become a mainstream treatment modality across the entire prostate disease spectrum

BioRestorative Therapies and Cartessa Aesthetics collaborate to build a vertically integrated, best-in-class biocosmeceutical platform

PharmaJet creates two SABs

William Blair starts Solid Biosciences at OP

LENZ Therapeutics completes merger with Graphite Bio

Profound Medical in collaboration with Siemens Healthineers to expand access to the TULSA procedure to treat prostate disease

Studies validate advantages of administering drugs to pets via IntelGenx’s VetaFilm platform

BioRestorative Therapies posts positive preliminary Phase 2 data for cLDD

Sigyn announces reverse split to support uplist to Nasdaq

Subscribe